There is a newer version of the record available.

Published October 7, 2019 | Version v1
Journal article

Performance of 99mTc-aprotinin scintigraphy for diagnosing light chain (AL) cardiac amyloidosis confirmed by endomyocardial biopsy

  • 1. Toho University Medical Center Ohashi Hospital. Division of Cardiovascular Medicine (Japan)
  • 2. National Center for Global Health and Medicine. Department of Cardiovascular Medicine (Japan)
  • 3. National Center for Global Health and Medicine. Division of Nuclear Medicine (Japan)
  • 4. The University of Tokyo. Department of Cardiovascular Medicine (Japan)
  • 5. Internal medicine Tokyo-Kita Medical Center. Department of Hematology (Japan)

Description

Background

: Light chain (AL) cardiac amyloidosis is associated with a poor prognosis. Diagnosing at an early stage is critical for treatment and the management of cardiac complication.

Purpose

: We aimed to evaluate the diagnostic performance of 99mTc-aprotinin images in patients with AL cardiac amyloidosis.

Methods and Results

: 99mTc-aprotinin scintigraphy and endomyocardial biopsy were performed in 10 patients with suspected amyloidosis. Endomyocardial biopsy showed amyloid deposits in 5 of 10 patients. 99mTc-aprotinin (planer image) was positive in 4 of 5 patients who had amyloid deposits in endomyocardial biopsy. On the other hand, all 5 patients without amyloid deposits were negative in planer image. 99mTc-aprotinin (SPECT/CT image) was positive in all 5 patients who had amyloid deposits.

Conclusions

: 99mTc-aprotinin scintigraphy is valuable for the non-invasive diagnosis of AL cardiac amyloidosis.

Additional details

Identifiers

Publishing Information

Journal Title
Journal of Nuclear Cardiology (Online)
Journal Volume
27
Journal Issue
4
Journal Page Range
p. 1145-1153
ISSN
1532-6551

Optional Information

Copyright
Copyright (c) 2019 © American Society of Nuclear Cardiology 2019